Reapplix is a regenerative medicine company offering a new solution to an old challenge.
Our mission is to change the life of patients with non-healing wounds by providing them with a new role in the management of their own wound.
Our promise is to provide clinicians with the tools to harness the patients’ own power from the patients’ blood without additional additives. We offer a proven alternative to other available wound management solutions such as those derived from donated cultured cells, human cadavers, placentas or animal derived collagen.
Founded in 2008, Reapplix is a privately held wound care company backed by leading Danish institutional investors that has developed a novel platform technology for Regenerative Medicine. Its innovative, patented 3C Patch® System draws on the individual patient’s capacity to heal and is clinically proven to accelerate the healing of diabetic foot ulcers. Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category.
Reapplix 3C Patch® therapy recommended for enhancement of healing diabetic foot ulcers by international working group on the diabetic foot (IWGDF)
The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of Reapplix’s technology, the 3C Patch®, an autologous combined leucocyte, platelet and fibrin, as an adjunctive treatment. Press release
New Publication in The Lancet Diabetes & Endocrinology
The positive outcome data of an independent Randomized Controlled Trial (RCT) of 3C Patch® was published in The Lancet Diabetes & Endocrinolocy on September 19, 2018.1 The results have also been presented at many scientific meetings in USA and Europe including the American Diabetes Association 78th Scientific Sessions meeting, June 2018, the Diabetic Foot Study Group Conference September 2018, and at the annual meeting of the European Association for the Study of Diabetes (EASD), October 2018.
1. Game F., Jeffcoate W., Tarnow L., Jacobsen JL., Whitham DJ., Harrison EF., Ellender SJ., Fitzsimmons D., Löndahl M., LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden:an observer-masked randomized controlled trial. www.thelancet.com/diabetes-endocrinology. Published online September 19, 2018. The Lancet publication